Annovis Bio, Inc.
NYSE:ANVS
1.53 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 19.995 | 38.791 | 16.516 | 8.479 | 3.054 | 0.776 | 0.112 | 0.273 |
| General & Administrative Expenses
| 6,699.481 | 6.244 | 8.996 | 6.058 | 3.586 | 0.829 | 0.602 | 0.409 |
| Selling & Marketing Expenses
| -6,692.782 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 6.699 | 6.244 | 8.996 | 6.058 | 3.586 | 0.829 | 0.602 | 0.409 |
| Other Expenses
| 0 | 0 | 0 | -0.037 | -1.157 | -0.735 | 0 | 0 |
| Operating Expenses
| 26.695 | 45.035 | 25.511 | 14.5 | 5.483 | 0.871 | 0.714 | 0.682 |
| Operating Income
| 0 | -45.035 | -25.511 | -14.537 | -6.64 | -1.606 | -0.714 | -0.682 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0 | -11.169 | 0.183 | 0.05 | 1.178 | 0.615 | 0 | 0 |
| Income Before Tax
| -24,590.375 | -56.204 | -25.329 | -14.487 | -5.462 | -0.991 | -0.714 | -0.682 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -24,565.785 | 0 | -0.183 | -0.05 | -1.205 | -0.694 | -0 | -0.682 |
| Net Income
| -24,590.375 | -56.204 | -25.146 | -14.437 | -4.257 | -0.297 | -0.714 | -0.682 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2,018.5 | -6.23 | -3.08 | -1.89 | -0.67 | -0.066 | -0.16 | -0.16 |
| EPS Diluted
| -2,009.77 | -6.23 | -3.08 | -1.89 | -0.67 | -0.066 | -0.16 | -0.16 |
| EBITDA
| -22.737 | -45.035 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |